论文部分内容阅读
慢性肾脏病（ CKD）骨矿物质代谢紊乱（ CKD －MBD）是CKD常见并发症之一。其主要临床表现为钙磷代谢异常、继发性甲状旁腺功能亢进、骨骼成分与结构改变和血管及软组织钙化。CKD－MBD 严重影响患者的生活质量及预后。近年来研究表明，成纤维细胞生长因子23（ FGF23）－Klotho系统在骨－肾－甲状旁腺轴中起重要作用，参与骨－矿物质代谢的调控。随着研究的深入， FGF23－Klotho轴有望成为CKD－MBD诊断和治疗的新靶点。“,”Chronic kidney disease (CKD) mineral and bone metabolism disorder(CKD-MBD) is one of the common complication of CKD .The main clinical manifestations include:abnormality of calcium phosphor-us metabolism,secondary hyperparathyroidism,skeletal composition and structure change ,vascular and soft tissue calcification.CKD-MBD has a serious impact on the quality of life and prognosis of the patients .Recent studies show that:the FGF23-Klotho system plays an important role in the “bone and kidneyp/arathyroid”axis,and it is involved in the regulation of bone mineral metabolism .With the deepening of the research on FGF23,the FGF23-Klotho axis is expected to be a new target in the diagnosis and treatment of CKD -MBD.